Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

October 29, 2020

Study Completion Date

April 2, 2021

Conditions
Diabetic Foot UlcerDeep Diabetic Foot Ulcer
Interventions
COMBINATION_PRODUCT

Dermacell

Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.

COMBINATION_PRODUCT

Integra

Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LifeNet Health

INDUSTRY

lead

Baylor College of Medicine

OTHER

NCT03476876 - Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter